Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;28(2):187-93.
doi: 10.1007/s10637-009-9218-8. Epub 2009 Jan 17.

The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug

Miguel Muñoz  1 , Marisa Rosso
Affiliations

The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug

Miguel Muñoz et al. Invest New Drugs. 2010 Apr.

Abstract

Aprepitant is a selective high-affinity antagonist of human substance P (SP)/Neurokinin-1 (NK-1) receptors. Until now this drug has been used as anxiolytic, antidepressant and antiemetic. It has been demonstrated that SP induces cell proliferation and NK-1 receptor antagonists different to aprepitant inhibit growth in several human cancer cell lines, where NK-1 receptors are overexpressed. The purpose of this study is to demonstrate the antitumor action of aprepitant. We performed an in vitro study of the growth inhibition capacity of the NK-1 receptor antagonist aprepitant against glioma, neuroblastoma, retinoblastoma and pancreas, larynx, gastric and colon carcinomas cell lines. Coulter counter was used to determine viable cell numbers followed by application of the MTS colorimetric method. Furthermore, a DAPI method was applied to demonstrate apoptosis. We have demonstrated: aprepitant at (5-70 microM) concentration elicits growth cell inhibition in a concentration dependent manner in all tumor cell line studied. Maximum inhibition (100%) was observed when the aprepitant was administered at a concentration of > or = 70 microM in all tumor cell lines studied. The specific antitumor action of aprepitant occurs through the NK-1 receptor and tumor cells death was by apoptosis pathway. These findings reported here for the first time indicate that aprepitant is a new and promising broad spectrum antitumor drug in the treatment of cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Intern Med. 2001 Jan;249(1):27-40 - PubMed
    1. Tumour Biol. 2008;29(4):245-54 - PubMed
    1. Behav Pharmacol. 2003 Feb;14(1):87-95 - PubMed
    1. J Neurochem. 2002 Nov;83(3):613-22 - PubMed
    1. Invest New Drugs. 2008 Apr;26(2):111-8 - PubMed

Publication types

LinkOut - more resources